Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  therapeutic tumor infiltrating lymphocytes
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-23 of 23 for your search:
Start Over
T-Cells Transduced With Either CXCR2 or Nerve Growth Factor Receptor (NGFR)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 14 and over
Sponsor: NCI, Other
Protocol IDs: 2009-0471, 2RO1CA116206-06, NCI-2014-02655, NCT01740557
Vemurafenib and TIL Therapy for Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: MM1414, NCT02354690
Peginterferon and TIL Therapy for Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: MM1413, NCT02379195
Tumor-Infiltrating Lymphocytes and Low-Dose Interleukin-2 Therapy Following Cyclophosphamide and Fludarabine in Patients With Pleural Mesothelioma
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: TILs-003-Meso, NCT02414945
Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CD-2007-01, NCT00610389
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110260, 11-C-0260, NCT01468818
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 120116, 12-C-0116, NCT01585428
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-16992, NCT01659151
Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2643.00, NCI-2013-00486, P30CA015704, NCT01807182
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI
Protocol IDs: 130093, 13-C-0093, NCT01814046
Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: J1343, NA_00084466, NCT01858558
Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: TILs-002-MEL, NCT01883323
Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 66
Sponsor: NCI
Protocol IDs: 140022, 14-C-0022, NCT01993719
TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11_DOG14_12, 2013-001071-20, NCT01995344
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 66
Sponsor: NCI
Protocol IDs: 140062, 14-C-0062, NCT02111863
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI
Protocol IDs: 140104, 14-C-0104, NCT02133196
A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: TIL-TREATMENT-0614, NCT02375984
Phase II Trial of TIL Following CCRT in Patients With Locoregionally Advanced NPC
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: NPC and TIL, NCT02421640
A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: SenU-200902002-2, NCT01462903
A Phase I Trial of Anti-PD-1, Anti-CD137 and TIL
Phase: Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other, Pharmaceutical / Industry
Protocol IDs: MCC-17429, NCT01909206
T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 74
Sponsor: Other
Protocol IDs: MAT-02, 2012-000450-63, NCT01946373
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-17057, CA184-213, NCT01701674
Start Over